Literature DB >> 31673562

Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma: role of salvage surgery.

Hyun Yang1,2, Pil Soo Sung1,2, Jaejun Lee1,2, Seung Kew Yoon1,3, Eun Sun Jung4, Cheon-Soo Park5, Si Hyun Bae1,2.   

Abstract

Entities:  

Year:  2019        PMID： 31673562      PMCID： PMC6791981          DOI： 10.21037/hbsn.2019.08.10

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  5 in total

1.  Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.

Authors:  Thomas Yau; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Yoon-Koo Kang; Ming-Mo Hou; Kazushi Numata; Winnie Yeo; Akhil Chopra; Masafumi Ikeda; Ryoko Kuromatsu; Michihisa Moriguchi; Yee Chao; Huanyu Zhao; Jeffrey Anderson; Christine Dela Cruz; Masatoshi Kudo
Journal:  J Hepatol       Date:  2019-06-07       Impact factor: 25.083

2.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Authors:  Alexander C Huang; Michael A Postow; Robert J Orlowski; Rosemarie Mick; Bertram Bengsch; Sasikanth Manne; Wei Xu; Shannon Harmon; Josephine R Giles; Brandon Wenz; Matthew Adamow; Deborah Kuk; Katherine S Panageas; Cristina Carrera; Phillip Wong; Felix Quagliarello; Bradley Wubbenhorst; Kurt D'Andrea; Kristen E Pauken; Ramin S Herati; Ryan P Staupe; Jason M Schenkel; Suzanne McGettigan; Shawn Kothari; Sangeeth M George; Robert H Vonderheide; Ravi K Amaravadi; Giorgos C Karakousis; Lynn M Schuchter; Xiaowei Xu; Katherine L Nathanson; Jedd D Wolchok; Tara C Gangadhar; E John Wherry
Journal:  Nature       Date:  2017-04-10       Impact factor: 49.962

3.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 4.  Mechanisms of resistance to immune checkpoint inhibitors.

Authors:  Russell W Jenkins; David A Barbie; Keith T Flaherty
Journal:  Br J Cancer       Date:  2018-01-02       Impact factor: 7.640

5.  Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas.

Authors:  Qi Zhang; Yu Lou; Jiaqi Yang; Junli Wang; Jie Feng; Yali Zhao; Lin Wang; Xing Huang; Qihan Fu; Mao Ye; Xiaozhen Zhang; Yiwen Chen; Ce Ma; Hongbin Ge; Jianing Wang; Jiangchao Wu; Tao Wei; Qi Chen; Junqing Wu; Chengxuan Yu; Yanyu Xiao; Xinhua Feng; Guoji Guo; Tingbo Liang; Xueli Bai
Journal:  Gut       Date:  2019-06-21       Impact factor: 23.059
  5 in total
  2 in total

1.  Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.

Authors:  Dong-Jun Park; Pil-Soo Sung; Gil-Won Lee; Sungwoo Cho; Sung-Min Kim; Byung-Yoon Kang; Wonhee Hur; Hyun Yang; Soon-Kyu Lee; Sung-Hak Lee; Eun-Sun Jung; Chang-Ho Seo; Joseph Ahn; Ho-Joong Choi; Young-Kyoung You; Jeong-Won Jang; Si-Hyun Bae; Jong-Young Choi; Seung-Kew Yoon
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 2.  Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma.

Authors:  Pil Soo Sung
Journal:  Clin Mol Hepatol       Date:  2021-10-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.